GPX4 and metabolic dysfunction-associated steatohepatitis: CSP inhibits the AMPK-mTOR pathway, restores autophagy and ferroptosis markers such as GPX4 and Nrf-2, and alleviates non-alcoholic steatohepatitis by inhibiting autophagic ferroptosis (Liang et al., 2024).